Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Status:
Recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
Patients suffering from diffuse large B-cell lymphoma (DLBCL) who relapse within 12 months of
chemotherapy usually undergo salvage therapies, followed by autologous transplant with a low
success rate. These treatments for relapse have significant toxicities and may not be
tolerated well by the patients. These patients need an effective means of identifying relapse
at an early time point to be treated effectively. Detection of circulating tumor DNA (ctDNA)
has been reported to be a sensitive and more specific method to detect relapse at an early
stage compared to PET/ CT scans. Purpose of this trial is to monitor patients who have
undergone successful chemotherapy for the presence of ctDNA. Patients who test positive for
ctDNA would be treated with Nivolumab for a period of 2 years to avoid complete relapse.